Incorporating newer agents in the treatment of acute myeloid leukemia

Renju V Raj; Sameem M Abedin; Ehab Atallah

doi:10.1016/j.leukres.2018.10.008

Incorporating newer agents in the treatment of acute myeloid leukemia

Leuk Res. 2018 Nov:74:113-120. doi: 10.1016/j.leukres.2018.10.008. Epub 2018 Oct 19.

Authors

Renju V Raj¹, Sameem M Abedin², Ehab Atallah³

Affiliations

¹ Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: [email protected].
² Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States.
³ Divison of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: [email protected].

PMID: 30401522
DOI: 10.1016/j.leukres.2018.10.008

Abstract

Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.

Keywords: AML; CPX-351; Gemtuzumab; IDH inhibitor; Midostaurin; Venetoclax.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Drug Approval
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents